Moderna
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Moderna and other ETFs, options, and stocks.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
MRNA Key Statistics
MRNA News
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript May 2, 2024 Moderna, Inc. beats earnings expectations. Reported EPS is $-3.07, expectations were $...
Moderna, Inc. (NASDAQ:MRNA) just released its quarterly report and things are looking bullish. Revenues of US$167m beat estimates by a substantial 33% margin. U...
Moderna Inc (NASDAQ:MRNA) faces a significant decrease in revenue and net income, reflecting a 91% drop in total revenue and a substantial net loss in Q1 2024 c...
Analyst ratings
48%
of 25 ratingsMore MRNA News
Jefferies analyst Michael Yee raised the firm’s price target on Moderna (MRNA) to $155 from $125 and keeps a Buy rating on the shares following a “nice” quarter...
Moderna (NASDAQ:MRNA) First Quarter 2024 Results Key Financial Results Revenue: US$167.0m (down 91% from 1Q 2023). Net loss: US$1.18b (down from US$79.0m pro...
Moderna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells the Sp...
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars Thursday, Moderna Inc (NASDAQ:MRNA) reporte...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration After topping expectations with first quarter revenue and adjusted ear...
With its Q1 2024 financials on Thursday, Moderna (NASDAQ:MRNA) highlighted its upcoming RSV vaccine, noting that the company expects U.S. regulators to recommen...
